BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with ...
BIMZELX® (bimekizumab-bkzx), the first IL-17A and IL-17F inhibitor, is FDA-approved for treating moderate-to-severe plaque psoriasis in adults. Supported by three Phase 3 trials, it offers rapid, lasting skin clearance, with 85-91% achieving clear or almost clear skin by week 16. UCB anticipates global peak sales exceeding €4 billion.
Reference News
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with ...
BIMZELX® (bimekizumab-bkzx), the first IL-17A and IL-17F inhibitor, is FDA-approved for treating moderate-to-severe plaque psoriasis in adults. Supported by three Phase 3 trials, it offers rapid, lasting skin clearance, with 85-91% achieving clear or almost clear skin by week 16. UCB anticipates global peak sales exceeding €4 billion.